论文部分内容阅读
目的观察氨氯地平联合阿托伐他汀钙治疗高血压合并冠心病的临床疗效。方法选取2013年1月-2015年12月医院收治的高血压合并冠心病患者90例,随机分为研究组与对照组各45例。对照组予氨氯地平治疗,研究组在对照组基础上加予阿托伐他汀钙治疗。比较2组临床效果,血压、血脂水平变化及不良反应发生率。结果研究组总有效率为91.1%明显高于对照组的73.3%,研究组心电图改善总有效率为88.9%明显优于对照组的71.1%,差异均有统计学意义(P<0.05)。2组治疗后收缩压、舒张压及血脂水平与治疗前相比均明显降低,且研究组更低于对照组,差异亦均有统计学意义(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论氨氯地平联合阿托伐他汀钙治疗高血压合并冠心病,临床效果好,能有效调控血压及血脂水平,且不会提升不良反应发生率,安全性较高,值得临床推广应用。
Objective To observe the clinical efficacy of amlodipine combined with atorvastatin calcium in the treatment of patients with hypertension and coronary heart disease. Methods From January 2013 to December 2015, 90 patients with hypertension and coronary heart disease admitted to the hospital were randomly divided into study group and control group, 45 cases each. The control group was treated with amlodipine, and the study group was given atorvastatin calcium treatment on the basis of the control group. The clinical effects, blood pressure, blood lipid levels and the incidence of adverse reactions in the two groups were compared. Results The total effective rate was 91.1% in the study group and 73.3% in the control group. The total effective rate in the study group was 88.9%, which was significantly better than that in the control group (71.1%, P <0.05). The systolic blood pressure, diastolic blood pressure and blood lipid levels of the two groups were significantly lower than those before treatment, and the study group was lower than the control group, the difference was also statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Amlodipine combined with atorvastatin calcium in patients with hypertension and coronary heart disease has good clinical effect and can effectively regulate blood pressure and blood lipid levels without increasing the incidence of adverse reactions and safety. It is worthy of clinical application.